- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01426074
DCE-MRI PET Bevacizumab Study in Rectal Cancer
20. august 2018 opdateret af: Abramson Cancer Center of the University of Pennsylvania
A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer
This study will determine the following: the response rate (including pathological CR rate), TTP, and complications of treatment in patients with rectal cancer treated with FOLFOX bevacizumab, the alteration of tumor blood flow (assessed by DCE-MRI as percentage change in Ktrans) after 1 cycle of bevacizumab therapy compared to baseline value in patients treated with FOLFOX alone and those treated with bevacizumab at 5 mg/kg., the degree of hypoxis (measured by tumor uptake of the 2-nitroimidazole EF5) induced by bevacizumab treatment and its relationship to changes in tumor blood flow, and the degree of apoptosis (measured by tumor uptake of di-annexin V) induced by bevacizumab treatment and its relationship to changes in tumor blood flow.
Studieoversigt
Status
Trukket tilbage
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The primary objectives of this study will determine the following: the response rate (including pathological CR rate), TTP, and complications of treatment in patients with rectal cancer treated with FOLFOX bevacizumab, the alteration of tumor blood flow (assessed by DCE-MRI as percentage change in Ktrans) after 1 cycle of bevacizumab therapy compared to baseline value in patients treated with FOLFOX alone and those treated with bevacizumab at 5 mg/kg., the degree of hypoxis (measured by tumor uptake of the 2-nitroimidazole EF5) induced by bevacizumab treatment and its relationship to changes in tumor blood flow, and the degree of apoptosis (measured by tumor uptake of di-annexin V) induced by bevacizumab treatment and its relationship to changes in tumor blood flow.
The secondary objectives of this study is to determine in an exploratory fashion the relationship between tumor blood flow, hypoxia induction, and apoptosis induction , and time to progression in patients continuing on to receive Bevacizumab 5 mg/kg, to analyze archival tumor from the patients treated in this trial for mutations in the MKK7 and SEK1 genes, and by semi-quantitative IHC for these and other relevant proteins, to determine the relationship between vascular proliferation as measured by DCE-MRI and markers of endothelial cell proliferation, and to obtain pilot data on whether assays that measure vascular endothelial cell mitogenic stimulation and mitogenic activity may predict response to therapy, time to progression and overall survival in patients receiving bevacizumab 5 mg/kg.
Undersøgelsestype
Interventionel
Fase
- Fase 2
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patients must have histologically documented advanced or metastatic adenocarcinoma of the rectum, T3 or T4, N any, M0 or M1. Patients must have available and identified tissue for immunohistochemical analysis and agree to submit it for the correlative endpoints. When available, formalin-fixed,paraffin-embedded tissue from previous biopsy or surgical resection will suffice.
- Patients must measurable disease as defined by the RECIST criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20mm with conventional techniques on either CT, MRI, or EUS. marker (CEA) elevation alone is in sufficient for entry.
- Patients may have had prior adjuvant treatment of rectal cancer. The prior treatment regimen must not have included bevacizumab but may have included oxaliplatin and the last dose of chemotherapy must have been > 6 months prior to study entry. Patients with prior radiotherapy are acceptable. It must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated.
- Patients with prior malignancies other than colorectal cancer are allowed, provided they have been treated with curative, intent, and have no evidence of recurrence of that malignancy.
- Patients must be age 18 years or older.
- Patients must have an ECOG performance status of 0-1.
- The following required required Initial Laboratory Values should be obtained within 4 weeks of the start of treatment:
Granulocytes ≥ 1,500/ml Platelet Count ≥ 100,000/ml Creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal AST ≤ 5 x upper limit of normal Urine: Urine protein: creatinine ration ≤ 1.0 at screening
- Patients must not be pregnant or lactating as chemotherapy is though to present substantial risk to the fetus/infant
- Patients must have a life expectancy of greater than three months.
- Patients must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients may not be receiving any other investigational agents.
- Patients with the following contraindication to MRI are excluded: Hypersensitivity to gadolinium Contraindicated metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI compatible mechanical and/or electrical device, or metallic fragments.
- Patients with severe claustrophobia
- Patients with a history of allergic reactions attributed to Flagyl (metronidazole) which has a chemical structure similar to EF5 are excluded.
- Patients with T1 or T2 N0M0 disease are not eligible.
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days to Day 0, anticipation of need for major surgical procedure during the course of the study. Minor surgical procedures such as port placement, fine needle aspirations or core biopsies within 3 days prior to Day 0.
- Patients with serious nonhealing wounds, ulcers, or bone fractures.
- Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
- Patients with a history of myocardial infarction, unstable angina, or cerebrovascular accident < 6 months prior to registration.
- Patients with clinically significant peripheral vascular disease.
- Patients with New York Heart Association Class II or greater congestive heart failure (Class II is defined as symptoms of fatigue, dyspnea or other symptoms with ordinary physical activity) See Appendix E.
- Patients using oral or parenteral anticoagulation are not excluded provided they are on a stable dose of anticoagulant.
- patients with pre-existing hypertension should be on a stable antihypertensive regimen and have a blood pressure ≤ 150/100 mmHg at the time of enrollment.
- Patients must not have known brain metastases because the study drug has not been adequately tested in this setting.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Pathologic Complete Response (pCR)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. august 2011
Primær færdiggørelse (Faktiske)
11. juni 2014
Studieafslutning (Faktiske)
11. juni 2014
Datoer for studieregistrering
Først indsendt
29. august 2011
Først indsendt, der opfyldte QC-kriterier
30. august 2011
Først opslået (Skøn)
31. august 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
21. august 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
20. august 2018
Sidst verificeret
1. august 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Tarmsygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Kolorektale neoplasmer
- Rektale neoplasmer
- Lægemidlers fysiologiske virkninger
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Bevacizumab
Andre undersøgelses-id-numre
- UPCC 05209
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Endetarmskræftpatienter
-
The University of Texas at ArlingtonAgency for Healthcare Research and Quality (AHRQ)RekrutteringPatientengagement | Patient Empowerment | Patient aktiveringForenede Stater
-
Columbia AsiaAfsluttetPatient Compliance | Læge-patient forholdIndien
-
University of AarhusUkendtPatientengagement | Patient Empowerment | Patient Compliance
-
Peking Union Medical College HospitalAfsluttetPatient efter hjerteklapkirurgi | Patient med langvarig mekanisk ventilationKina
-
University of British ColumbiaAfsluttetMeddelelse | Tilfredshed | Læge-patient forhold | Sygeplejerske-patient relationerCanada
-
University of California, San DiegoPatient-Centered Outcomes Research Institute; University of Massachusetts... og andre samarbejdspartnereAfsluttetPatientengagement | Læge-patient forhold | Lægens rolle | Patient aktiveringForenede Stater
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityAfsluttet
-
University of Dublin, Trinity CollegeDublin Dental University HospitalRekrutteringOverholdelse, patientIrland
-
Fondazione Policlinico Universitario Agostino Gemelli...Ikke rekrutterer endnuHjertekirurgisk patient
-
AltaMed Health Services CorporationNational Institute on Aging (NIA); University of Southern CaliforniaRekrutteringPatient GenindlæggelseForenede Stater
Kliniske forsøg med Bevacizumab 5 mg/kg
-
Eisai Co., Ltd.Afsluttet
-
Crucell Holland BVNational Institute of Allergy and Infectious Diseases (NIAID)Afsluttet
-
Crucell Holland BVNational Institute of Allergy and Infectious Diseases (NIAID)Afsluttet
-
Hoffmann-La RocheAfsluttetKolorektal cancerFrankrig, Israel, Italien, Spanien, Sverige, Hong Kong, Australien, Canada, Schweiz, Forenede Stater, Irland, Danmark, Tyskland, Taiwan, Den Russiske Føderation, Kina, New Zealand, Østrig, Det Forenede Kongerige, Ungarn, Thailand, ... og mere
-
aTyr Pharma, Inc.Kyorin Pharmaceutical Co.,LtdRekrutteringPulmonal sarkoidoseForenede Stater, Japan, Holland, Spanien, Det Forenede Kongerige, Frankrig, Italien, Brasilien, Tyskland, Puerto Rico
-
RezoluteRekrutteringMedfødt hyperinsulinismeBulgarien, Canada, Danmark, Frankrig, Georgien, Tyskland, Grækenland, Israel, Oman, Qatar, Saudi Arabien, Spanien, Kalkun, Forenede Arabiske Emirater, Det Forenede Kongerige, Vietnam
-
Bill & Melinda Gates Medical Research InstituteRekrutteringMalariaForenede Stater
-
EA Pharma Co., Ltd.Afsluttet
-
Merck Sharp & Dohme LLCAfsluttet
-
Centocor, Inc.AfsluttetLungefibroseForenede Stater, Canada, Holland, Belgien, Tyskland